Spots Global Cancer Trial Database for HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Lung Cancer
Official Title: HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Cancer: Clinical Trial
Study ID: NCT02523404
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA）for lung cancer.
Detailed Description: By enrolling patients with lung cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA）for lung cancer.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Central laboratory in Fuda cancer hospital, Guangzhou, Guangdong, China
Contact Details
Name: Lizhi Niu, PhD
Affiliation: Fuda Cancer Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
